Chiltern Releases System for Capturing, Managing, and Reporting Clinical Research Data
London, U.K., and Wilmington, N.C.; June 8, 2017 - Chiltern, a global contract research organization, announced the release of its new Medidata Rave® Value Accelerators, a system of tools designed to capture, manage, and report clinical research data. The tools streamline the clinical trial process and help trial sponsors cut the time, cost, and effort of bringing a new device to market.
“Our partnership with Medidata and its industry-leading platform aligns with our strategy providing an exceptional customer experience around best-in-class technologies,” said Mark Penniston, executive vice president, clinical analytics, and general manager at Chiltern. “Currently our Data & Analysis team leads the field in providing the latest platforms and technologies and the Medidata Rave Value Accelerators support our stronghold in the technology space.”
Included are three accelerator tools: the Chiltern EC Reviewer for Medidata Rave®, Chiltern EC Detector for Medidata Rave®, and Chiltern EC Analyzer for Medidata Rave®. They are designed to create flexibility for users, helping them accommodate their workflow environments, and they are scalable from one study to hundreds and from Phase I to global Phase IV studies.
The tools function in any type of study requirement-from simple to complex-out of the box or customized to our customer’s process. Not only can sponsors select which tools are appropriate for their needs but they can be used anytime and anywhere, and by multiple users during the setup and conduct of the trial.
Over the course of the next year there will be more tools available. To learn more about Chiltern’s services and technologies, visit Chiltern.com or request a demo at the Drug Information Association Annual Meeting in Chicago, June 19–21, in booth 1807.
About Chiltern
Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.
CONTACT:
Lea Studer
SCORR Marketing
308-237-5567
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
